Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
Breast Cancer Res. 2011 Jun 27;13(3):212. doi: 10.1186/bcr2890.
Breast cancer comprises a collection of diseases with distinctive clinical, histopathological, and molecular features. Importantly, tumors with similar histological features may display disparate clinical behaviors. Gene expression profiling using microarray technologies has improved our understanding of breast cancer biology and has led to the development of a breast cancer molecular taxonomy and of multigene 'signatures' to predict outcome and response to systemic therapies. The use of these prognostic and predictive signatures in routine clinical decision-making remains controversial. Here, we review the clinical relevance of microarray-based profiling of breast cancer and discuss its impact on patient management.
乳腺癌包括一组具有独特临床、组织病理学和分子特征的疾病。重要的是,具有相似组织学特征的肿瘤可能表现出不同的临床行为。使用微阵列技术的基因表达谱分析提高了我们对乳腺癌生物学的认识,并导致了乳腺癌分子分类学和多基因“特征”的发展,以预测预后和对系统治疗的反应。这些预后和预测特征在常规临床决策中的应用仍然存在争议。在这里,我们回顾了基于微阵列的乳腺癌分析的临床相关性,并讨论了其对患者管理的影响。